P- and E- selectin in venous thrombosis and non-venous pathologies.
J Thromb Haemost
; 20(5): 1056-1066, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1822054
ABSTRACT
Venous thromboembolism is a very common and costly health problem worldwide. Anticoagulant treatment for VTE is imperfect all have the potential for significant bleeding, and none prevent the development of post thrombotic syndrome after deep vein thrombosis or chronic thromboembolic pulmonary hypertension after pulmonary embolism. For these reasons, alternate forms of therapy with improved efficacy and decreased bleeding are needed. Selectins are a family (P-selectin, E-selectin, L-selectin) of glycoproteins that facilitate and augment thrombosis, modulating neutrophil, monocyte, and platelet activity. P- and E-selectin have been investigated as potential biomarkers for thrombosis. Inhibition of P-selectin and E-selectin decrease thrombosis and vein wall fibrosis, with no increase in bleeding. Selectin inhibition is a promising avenue of future study as either a stand-alone treatment for VTE or as an adjunct to standard anticoagulation therapies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Embolism
/
Thrombosis
/
P-Selectin
/
Venous Thrombosis
/
Venous Thromboembolism
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Thromb Haemost
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Affiliation country:
Jth.15689
Similar
MEDLINE
...
LILACS
LIS